FibroGen, Inc (NASDAQ:FGEN) Position Lowered by Rothschild Asset Management Inc.
Rothschild Asset Management Inc. reduced its position in shares of FibroGen, Inc (NASDAQ:FGEN) by 2.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 181,025 shares of the biopharmaceutical company’s stock after selling 4,980 shares during the period. Rothschild Asset Management Inc. owned approximately 0.26% of FibroGen worth $5,847,000 at the end of the most recent quarter.
Several other institutional investors have also made changes to their positions in FGEN. DekaBank Deutsche Girozentrale purchased a new stake in FibroGen during the first quarter valued at about $1,133,000. American Century Companies Inc. raised its stake in FibroGen by 35.0% in the first quarter. American Century Companies Inc. now owns 250,051 shares of the biopharmaceutical company’s stock valued at $6,164,000 after buying an additional 64,760 shares in the last quarter. Algert Global LLC raised its stake in FibroGen by 6.4% in the first quarter. Algert Global LLC now owns 24,322 shares of the biopharmaceutical company’s stock valued at $600,000 after buying an additional 1,466 shares in the last quarter. Wells Fargo & Company MN raised its stake in FibroGen by 29.0% in the first quarter. Wells Fargo & Company MN now owns 62,037 shares of the biopharmaceutical company’s stock valued at $1,529,000 after buying an additional 13,928 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its stake in FibroGen by 58.1% in the first quarter. Russell Investments Group Ltd. now owns 33,627 shares of the biopharmaceutical company’s stock valued at $829,000 after buying an additional 12,354 shares in the last quarter. 43.45% of the stock is currently owned by institutional investors.
FibroGen, Inc (FGEN) opened at 33.40 on Tuesday. The company’s 50-day moving average price is $32.84 and its 200 day moving average price is $27.51. FibroGen, Inc has a 52 week low of $15.60 and a 52 week high of $35.85. The company’s market cap is $2.34 billion.
FibroGen (NASDAQ:FGEN) last released its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.11. The company had revenue of $26.89 million during the quarter, compared to analysts’ expectations of $26.02 million. FibroGen had a negative return on equity of 36.41% and a negative net margin of 37.60%. On average, analysts anticipate that FibroGen, Inc will post ($1.85) EPS for the current year.
TRADEMARK VIOLATION WARNING: “FibroGen, Inc (NASDAQ:FGEN) Position Lowered by Rothschild Asset Management Inc.” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/08/fibrogen-inc-nasdaqfgen-position-lowered-by-rothschild-asset-management-inc.html.
Several equities research analysts recently issued reports on the company. BidaskClub lowered FibroGen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. William Blair restated an “outperform” rating on shares of FibroGen in a research note on Monday, June 26th. Jefferies Group LLC started coverage on FibroGen in a research note on Monday, July 10th. They set a “buy” rating and a $50.00 price objective for the company. Stifel Nicolaus restated a “buy” rating and set a $38.00 price objective (up from $32.00) on shares of FibroGen in a research note on Thursday, June 22nd. Finally, Goldman Sachs Group, Inc. (The) downgraded FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective for the company. in a research note on Friday, July 21st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $40.57.
In related news, insider K Peony Yu sold 10,000 shares of FibroGen stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $33.48, for a total transaction of $334,800.00. Following the completion of the sale, the insider now directly owns 226,507 shares of the company’s stock, valued at $7,583,454.36. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $27.40, for a total value of $54,800.00. Following the sale, the director now directly owns 36,000 shares of the company’s stock, valued at $986,400. The disclosure for this sale can be found here. Insiders sold a total of 409,974 shares of company stock valued at $12,647,338 over the last three months. Insiders own 14.90% of the company’s stock.
FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen, Inc (NASDAQ:FGEN).
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.